Matrix metalloproteinase-14 triggers an anti-inflammatory proteolytic cascade in endotoxemia

Alina Aguirre1, Jorge Blázquez-Prieto2, Laura Amado-Rodriguez2,3

  • 1Facultad de Ingeniería y Ciencias Agropecuarias, Universidad de las Américas, Quito, Ecuador.

Journal of Molecular Medicine (Berlin, Germany)
|January 26, 2017
PubMed

Insights

Matrix metalloproteinase-14 (MMP-14) plays a crucial anti-inflammatory role in sepsis by regulating MMP-2 activation and S100A9 levels, thus mitigating lung injury and mortality.

Area of Science:

  • Biochemistry
  • Immunology
  • Pathology

Background:

  • Matrix metalloproteinases (MMPs) modulate inflammatory responses.
  • MMP-14 is a key collagenase activating other enzymes.
  • The role of MMP-14 in sepsis-induced inflammation is not fully understood.

Purpose of the Study:

  • To investigate the role of MMP-14 in the pro-inflammatory response during endotoxemia and sepsis.
  • To determine the impact of MMP-14 deficiency on lung injury and mortality.
  • To explore the therapeutic potential of the MMP-14-MMP-2 axis in sepsis.

Main Methods:

  • Wildtype and Mmp14 knockout mice were challenged with lipopolysaccharide (LPS).
  • MMP levels, lung injury, and mortality were assessed.
  • Lung explants and patient serum samples were analyzed.

Main Results:

  • MMP-14 levels decreased in endotoxemic mice and septic patients.
  • Mmp14 knockout mice exhibited 100% mortality, severe lung injury, and impaired MMP-2 activation.
  • Absence of MMP-14 led to increased S100A9 levels, while exogenous MMP-2 ameliorated alarmin increase.
  • Septic patients showed reduced serum MMP-14 and activated MMP-2.

Conclusions:

  • The MMP-14-MMP-2 axis is downregulated in sepsis, contributing to a pro-inflammatory state.
  • MMP-14 deficiency exacerbates lung injury and mortality via S100A9 upregulation.
  • Targeting the MMP-14-MMP-2 pathway may offer therapeutic benefits for sepsis.